Access cutting-edge gynecologic cancers treatment through this clinical trial at a research site in Oklahoma City. Study-provided care at no cost to qualified participants.
Quick Self-Assessment
See if you qualify for this Oklahoma City location
Preparing your pre-screening questions…
Access gynecologic cancers specialists at no cost
This study follows strict safety protocols and ethical guidelines
All study-related gynecologic cancers treatment provided free
Check if you qualify for this gynecologic cancers clinical trial in Oklahoma City, OK
No-Cost Study Care
Local to Oklahoma City
Convenient for OK residents
Cutting-Edge Treatment
Access to innovative therapies
Expert Medical Care
Close monitoring by specialists
Possible Compensation*
For time and travel
*Compensation varies by study. Confirm details with coordinator.
Cancer is a condition where cells in a specific part of body grow and reproduce uncontrollably. The purpose of this study is to assess safety and tolerability of IMGN151 when given as monotherapy and in combination with other anti-cancer therapies in adult participants with gynecologic cancers. IMGN151 is an investigational drug being developed for the treatment of gynecologic cancers. Participants are placed in 1 of 4 groups, called treatment arms. Each group receives a different treatment. Around 377 participants with gynecologic cancers will be enrolled in the study at approximately 50 sites worldwide. Participants will receive intravenous infusions of IMGN151 as monotherapy or in combination with anti-cancer therapies according to their assigned study arm. In Arm A, participants will receive IMGN151 in combination with carboplatin on Day 1 of each cycle. In Arm B, participants will receive IMGN151 in combination with olaparib, twice a day (BID) on Day 1 of each cycle. In Arm C, participants will receive IMGN151 in combination with bevacizumab on Day 1 of each cycle. In Arm D, participants will receive IMGN151 as monotherapy on Day 1 of each cycle. In Arm E, participants will receive IMGN151 as monotherapy on Day 1 of each cycle. In Arm F, participants will receive IMGN151 as monotherapy on Day 1 of each cycle. The total study duration will be approximately 3 years. There may be higher treatment burden for participants in this trial compared to their standard of care. Participants will attend regular visits during the study at a hospital or clinic and may require frequent medical assessments, blood tests, and scans.
Sponsor: AbbVie
Yes, this clinical trial (NCT07024784) has an active research site in Oklahoma City, OK that is currently enrolling participants.
Clinical trials follow strict safety guidelines and ethical standards. This study has been reviewed and approved, and participants are closely monitored by medical professionals. You can withdraw at any time.
Many clinical trials offer compensation for your time and travel expenses. Specific compensation details will be discussed during the screening process. All study-related medical care is provided at no cost.
Absolutely. Participation is completely voluntary. You have the right to withdraw from the study at any time, for any reason, without penalty.
If you're searching for gynecologic cancers treatment options in Oklahoma City, OK, this clinical trial (NCT07024784) may be an excellent opportunity. Clinical trials provide access to cutting-edge treatments that aren't yet available to the general public, often at no cost to participants.
Our Oklahoma City research site is actively enrolling participants for this clinical trial. You'll receive care from experienced gynecologic cancers specialists who are at the forefront of medical research. All study-related care, including examinations, treatments, and monitoring, is provided at no cost to qualified participants.
Looking for more options? Browse all gynecologic cancers clinical trials near you to find additional studies recruiting in your area.
See all interstitial cystitis clinical trials recruiting in Oklahoma City — not just this study.
Browse Interstitial Cystitis Trials in Oklahoma City →